Neuronetics, Inc. Announces Virtual 2020 Annual Meeting of Stockholders
MALVERN, Pa., May 12, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (Nasdaq: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that its 2020 Annual Meeting of Stockholders will be held solely via live webcast due to the public health impact of the COVID-19 pandemic and out of an abundance of concern for the health and wellbeing of our employees, stockholders and directors. As previously announced, the 2020 Annual Meeting will be held on May 26, 2020 at 9:00 am ET.
Attending the Virtual Annual Meeting
To attend and participate in the virtual Annual Meeting of Stockholders, stockholders of record will need to visit and use their 16-digit control number (the “Control Number”) received in their notice to log in to this website. Beneficial owners of shares held in street name will need to follow the instructions provided by the broker, bank or other nominee that holds their shares. We would encourage stockholders to log in to this website and access the webcast before the meeting’s start time.
Asking Questions and Voting
As described in the proxy materials for the Annual Meeting, Neuronetics stockholders as of the close of business on April 3, 2020 (the record date) are entitled to join the live virtual meeting and shall be able to listen and vote remotely.
The proxy card included with the proxy materials previously distributed on or about April 13, 2020 will not be updated to reflect the change in location and may continue to be used to vote your shares in connection with the Annual Meeting. The Company encourages eligible stockholders to vote on the proposals prior to the Annual Meeting using the instructions provided in the proxy materials previously distributed.
Assistance with the Virtual Annual Meeting
Further instructions on how to attend, participate in and vote at the virtual Annual Meeting of Stockholders will be available at . A support line will also be available on the meeting website on the day of the virtual Annual Meeting should stockholders require assistance with logging in. Digital copies of the company’s proxy statement and 2019 Annual Report are available at . These materials also are available on the Company’s website at .
About Neuronetics
Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. Additional information can be found at .
Forward-Looking Statements
Statements contained herein that relate to the Company's 2020 Annual Meeting of Stockholders are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "will be", "will", "may" or other similar words or expressions often identify forward-looking statements. Such statements are based on current expectations only, and are subject to certain risks, uncertainties and assumptions, many of which are beyond our control. Among the factors that could cause the Company’s 2020 Annual Meeting logistical arrangements to change include: general business and economic conditions; imposition of restrictive governmental regulations implemented to address public health concerns; or operational delays or difficulties because of the novel coronavirus or similar diseases, or uncertainty regarding the same. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Mark R. Klausner
Westwicke Partners
443-213-0501
Media Contact:
Chelsey Manko
Vault Communications
610-455-2778
